Breaking

Isomorphic Labs Joins $1.8 Billion Virtual Biology Effort as It Pushes AI Drug Design Toward the Clinic

October 8, 2026 at 02:54 EDT

Foundation Models
Healthcare
Funding & M&A

Isomorphic Labs has joined a $1.8 billion cross-sector push to generate AI-ready biological data, while sharpening its public mission around using AI to "solve all disease." The AI-first drug-design company says the effort will support predictive models of biology and feed a broader plan to move AI-designed medicines toward the clinic.

Oct. 7, 2026 - Isomorphic Labs

AI drug design moves toward virtual biology

Isomorphic Labs joined a $1.8 billion effort to build AI-ready biology data as it scales IsoDDE, its drug-design engine, toward medicines that still need lab and clinical proof.

$1.8B

Virtual Biology Initiative commitment

$300M

Google DeepMind, Isomorphic Labs and Meta

$2.1B

Isomorphic Labs Series B

2-4 days

Reported agent search window

Benchmark jump in antibody interfaces

A proportional view of IsoDDE's reported high-fidelity antibody-antigen prediction gain over AlphaFold 3.

1xAlphaFold 3

2.3xIsoDDE

Why it matters: antibody interfaces are a hard class of protein-protein prediction, and higher fidelity can help prioritize designs before wet-lab testing.

From data to candidate molecules

1 - Measure

Cell response data across more conditions

2 - Model

Predictive systems for biology

3 - Design

IsoDDE searches chemical space

4 - Validate

Lab and clinical proof still decide

What supporters see

AI moving from structure prediction into molecule design
Open biology data as shared scientific infrastructure

What remains unproven

Benchmarks are not approved medicines
Safety and efficacy must survive clinical trials

Continue reading

The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.